Get started
Author

Alan J. Wilhelm

Observed names: A. Wilhelm, Alan J Wilhelm, Alan Wilhelm, Wilhelm, A.J., Wilhelm, Alan
OpenAlex ID: A5076108317
A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells
2018 · Yelena Kovtun, Gregory E. Jones, et al. · Blood Advances · 182
A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
2016 · Michael L. Miller, Nathan E. Fishkin, et al. · Molecular Cancer Therapeutics · 102
A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody–Drug Conjugates (ADCs)
2018 · Michael L. Miller, Manami Shizuka, et al. · Molecular Cancer Therapeutics · 56
PDF
Optimizing Lysosomal Activation of Antibody–Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers
2019 · Paulin L. Salomon, Emily E. Reid, et al. · Molecular Pharmaceutics · 51
A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation
2019 · Nicholas C. Yoder, Chen Bai, et al. · Molecular Pharmaceutics · 39
The Antibody-Drug Conjugate (ADC) IMGN779 Is Highly Active in Vitro and in Vivo Against Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations
2014 · Kathleen R Whiteman, Paul Noordhuis, et al. · Blood · 35
Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody–Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation
2019 · Chen Bai, Emily E. Reid, et al. · Bioconjugate Chemistry · 32
PDF
Inhibition of Spleen Tyrosine Kinase Attenuates Allergen-Mediated Airway Constriction
2013 · Lily Y. Moy, Yanlin Jia, et al. · American Journal of Respiratory Cell and Molecular Biology · 28
Effect of Linker Stereochemistry on the Activity of Indolinobenzodiazepine Containing Antibody–Drug Conjugates (ADCs)
2019 · Emily E. Reid, Katie E. Archer, et al. · ACS Medicinal Chemistry Letters · 20
Prime Editing Efficiently and Precisely Corrects Causative Mutation in Chronic Granulomatous Disease, Restoring Myeloid Function: Toward Development of a Prime Edited Autologous Hematopoietic Stem Cell Therapy
2023 · Jack M Heath, Jacob Stuart Orenstein, et al. · Blood · 18
IMGN632: A CD123-Targeting Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is Highly Active and Prolongs Survival in Acute Myeloid Leukemia (AML) Xenograft Models
2016 · Sharlene Adams, Alan Wilhelm, et al. · Blood · 17
Multiplex Prime Editing and PASSIGE TM for Non-Viral Generation of an Allogeneic CAR-T Cell Product
2023 · Emily J Pomeroy, Andrew V Anzalone, et al. · Blood · 16
Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody–Drug Conjugates (ADCs)
2019 · Katie E. Archer, Emily E. Reid, et al. · ACS Medicinal Chemistry Letters · 14
Design, synthesis and evaluation of novel, potent DNA alkylating agents and their antibody-drug conjugates (ADCs)
2019 · Emily E. Reid, Katie E. Archer, et al. · Bioorganic & Medicinal Chemistry Letters · 7
IMGN779, a Next Generation CD33-Targeting ADC, Combines Effectively with Cytarabine in Acute Myeloid Leukemia (AML) Preclinical Models, Resulting in Increased DNA Damage Response, Cell Cycle Arrest and Apoptosis In Vitro and Prolonged Survival In Vivo
2017 · Sharlene Adams, Meghan Kelly, et al. · Blood · 7
A CD123-Targeting Antibody-Drug Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid Leukemia (AML) Cells While Sparing Normal Bone Marrow Cells
2016 · Yelena Kovtun, Gregory Jones, et al. · Blood · 7
Abstract 647: SeriMabs: N-terminal serine modification enables modular, site-specific payload incorporation into antibody-drug conjugates (ADCs)
2015 · Luke Harris, Daniel Tavares, et al. · Cancer Research · 6
Abstract 2644: Antibody-drug conjugates (ADCs) with a novel DNA-alkylating agent, DGN462, are highly potent in vitro and in vivo against human cancer models
2014 · Kathleen Whiteman, Charlene Audette, et al. · Cancer Research · 6
Alternaria alternata induced inflammatory lung responses: a novel in vivo PK/PD model
2013 · Malgorzata Gil, Michael Caniga, et al. · Journal of Inflammation · 3
PDF
Abstract 213: Development of a probody-drug conjugate targeting EpCAM for the treatment of solid tumors
2019 · Yimao Liu, Rui Wu, et al. · Cancer Research · 2
Abstract 2965: In vitro and in vivo activity of a site-specific SeriMab antibody-drug conjugate (ADC) using an indolino-benzodiazepine DNA-alkylating agent
2016 · Dilrukshi Vitharana, Alan Wilhelm, et al. · Cancer Research · 1
Abstract 4504: Plasma pharmacokinetics and tumor accumulation in mice of IMGN779, an antibody-drug conjugate for acute myeloid leukemia
2015 · Katharine C. Lai, Prerak Shah, et al. · Cancer Research · 1
Abstract 645: Stability and efficacy comparison of site-specific and lysine-linked maytansinoid antibody-drug conjugates
2015 · Nicholas C. Yoder, Chen Bai, et al. · Cancer Research · 1
Abstract C162: Antibody-Drug Conjugates (ADCs) with novel IGN DNA-alkylating agents display potent antigen-specific activity against hematologic and solid tumor xenograft models.
2013 · Kathleen Whiteman, Holly Johnson, et al. · Molecular Cancer Therapeutics · 1
Characterization of a Novel, Potent and Selective Small Molecule Spleen Tyrosine Kinase (SYK) Inhibitor in In Vitro and In Vivo Models of Asthma.
2012 · M.A. Crackower, L.Y. Moy, et al. · Journal of Allergy and Clinical Immunology · 1
Works count: 58
Citation count: 653
H-index: 13
I10-index: 13
Year
Topic
Type